Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Pharmaceuticals Reports Second Quarter 2014 Financial Results and Program Updates
SAN DIEGO, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and six months ended June 30, 2014, and
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Second Quarter 2014 Financial Results
SAN DIEGO, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the second quarter ended June 30,
View HTML
Toggle Summary Conatus Pharmaceuticals to Relocate Corporate Headquarters
SAN DIEGO, July 7, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will relocate the company's corporate headquarters to a new leased
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, May 27, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentations at the following investor conferences in June:
View HTML
Toggle Summary Conatus Pharmaceuticals Reports First Quarter 2014 Financial Results and Program Updates
SAN DIEGO, May 13, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2014, and provided
View HTML
Toggle Summary Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients
SAN DIEGO, May 12, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2b clinical trial of its lead drug candidate,
View HTML
Toggle Summary Conatus Pharmaceuticals to Report First Quarter 2014 Financial Results
SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31,
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at Deutsche Bank Health Care Conference
SAN DIEGO, April 30, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs
View HTML
Toggle Summary Conatus Pharmaceuticals Reports 2013 Financial Results and Program Updates
SAN DIEGO, March 27, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the fourth quarter and full year ended December 31,
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Financial Results
SAN DIEGO, March 20, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the fourth quarter and full year
View HTML